{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:41:00Z","timestamp":1792665660196,"version":"4.5.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"DOI":"10.1007\/s10555-026-10387-2","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:13:04Z","timestamp":1792663984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The right patient, the right moment, the right therapy: reimagining precision oncology from the bedside"],"prefix":"10.1007","volume":"45","author":[{"given":"Lily","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4182-6058","authenticated-orcid":false,"given":"Bora","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"10387_CR1","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1200\/jco.19.03010","volume":"38","author":"KT Flaherty","year":"2020","unstructured":"Flaherty, K. T., Gray, R. J., Chen, A. P., et al. (2020). Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). Journal of Clinical Oncology, 38, 3883\u20133894. https:\/\/doi.org\/10.1200\/jco.19.03010","journal-title":"Journal of Clinical Oncology"},{"key":"10387_CR2","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2020-0024","volume":"6","author":"EB Maldonado","year":"2020","unstructured":"Maldonado, E. B., Parsons, S., Chen, E. Y., et al. (2020). Estimation of US patients with cancer who may respond to cytotoxic chemotherapy. Future Science OA, 6, Article Fso600. https:\/\/doi.org\/10.2144\/fsoa-2020-0024","journal-title":"Future Science OA"},{"key":"10387_CR3","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","volume":"4","author":"J Marquart","year":"2018","unstructured":"Marquart, J., Chen, E. Y., & Prasad, V. (2018). Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncology, 4, 1093\u20131098. https:\/\/doi.org\/10.1001\/jamaoncol.2018.1660","journal-title":"JAMA Oncology"},{"key":"10387_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.Cd-16-1396","volume":"7","author":"C Massard","year":"2017","unstructured":"Massard, C., Michiels, S., Fert\u00e9, C., et al. (2017). High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: Results of the MOSCATO 01 trial. Cancer Discovery, 7, 586\u2013595. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-1396","journal-title":"Cancer Discovery"},{"key":"10387_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong, C. H., Siah, K. W., & Lo, A. W. (2019). Estimation of clinical trial success rates and related parameters. Biostatistics, 20, 273\u2013286. https:\/\/doi.org\/10.1093\/biostatistics\/kxx069","journal-title":"Biostatistics"},{"key":"10387_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61034-3","volume":"16","author":"Q Zhu","year":"2025","unstructured":"Zhu, Q., Balasubramanian, A., Asirvatham, J. R., et al. (2025). Integrative spatial omics reveals distinct tumor-promoting multicellular niches and immunosuppressive mechanisms in Black American and White American patients with TNBC. Nature Communications, 16, Article 6584. https:\/\/doi.org\/10.1038\/s41467-025-61034-3","journal-title":"Nature Communications"},{"key":"10387_CR7","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1172\/jci70805","volume":"125","author":"J Zhao","year":"2015","unstructured":"Zhao, J., Zhao, D., Poage, G. M., et al. (2015). Death-associated protein kinase 1 promotes growth of p53-mutant cancers. Journal of Clinical Investigation, 125, 2707\u20132720. https:\/\/doi.org\/10.1172\/jci70805","journal-title":"Journal of Clinical Investigation"},{"key":"10387_CR8","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1158\/1078-0432.ccr-12-2986","volume":"19","author":"KD Yu","year":"2013","unstructured":"Yu, K. D., Zhu, R., Zhan, M., et al. (2013). Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 19, 2723\u20132733. https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-2986","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10387_CR9","doi-asserted-by":"publisher","unstructured":"Lehmann, B. D., Jovanovic. B., Chen, X., et al. (2016). Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PloS one,\u00a0\u00a011: e0157368.\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0157368.","DOI":"10.1371\/journal.pone.0157368"},{"key":"10387_CR10","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"B Lehmann","year":"2011","unstructured":"Lehmann, B., Bauer, J., Chen, X., et al. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation, 121, 2750\u20132767. https:\/\/doi.org\/10.1172\/JCI45014","journal-title":"Journal of Clinical Investigation"},{"issue":"eadu0031","key":"10387_CR11","doi-asserted-by":"publisher","first-page":"20260501","DOI":"10.1126\/sciadv.adu0031","volume":"12","author":"D Wylie","year":"2026","unstructured":"Wylie, D., Wang, X., Yao, J., et al. (2026). Pervasive enhanced transcription in inflammatory breast cancer tumors and PBMCs impacts RNA splicing and intronic RNAs in plasma. Science Advances, 12(eadu0031), 20260501. https:\/\/doi.org\/10.1126\/sciadv.adu0031","journal-title":"Science Advances"},{"key":"10387_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-43437-4","volume":"16","author":"JH Chen","year":"2026","unstructured":"Chen, J. H., Balema, W., Krishnamurthy, S., et al. (2026). CCR7 immune cell receptor expression in inflammatory breast cancer. Scientific Reports, 16, Article 13513. https:\/\/doi.org\/10.1038\/s41598-026-43437-4","journal-title":"Scientific Reports"},{"key":"10387_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05790-8","volume":"22","author":"F Bertucci","year":"2024","unstructured":"Bertucci, F., Guille, A., Lerebours, F., et al. (2024). Whole-exome profiles of inflammatory breast cancer and pathological response to neoadjuvant chemotherapy. Journal of Translational Medicine, 22, Article 969. https:\/\/doi.org\/10.1186\/s12967-024-05790-8","journal-title":"Journal of Translational Medicine"},{"key":"10387_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/lymphatics2040016","volume":"2","author":"J Wang","year":"2024","unstructured":"Wang, J., Hoffman, R. M., Ye, Y., et al. (2024). Lymphovascular tumoral emboli in inflammatory breast cancer result from haptotaxis-mediated encircling lymphangiogenesis. Lymphatics, 2, 195\u2013211. https:\/\/doi.org\/10.3390\/lymphatics2040016","journal-title":"Lymphatics"},{"key":"10387_CR15","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1158\/1538-7445.Am2026-4110","volume":"86","author":"A Shatta","year":"2026","unstructured":"Shatta, A., Chamorro, D. F., Nelson, B. E., et al. (2026). Abstract 4110: Genomic vulnerabilities and clinical behavior of metaplastic breast cancer through integrated registry and GENIE analysis. Cancer Research, 86, 4110\u20134110. https:\/\/doi.org\/10.1158\/1538-7445.Am2026-4110","journal-title":"Cancer Research"},{"key":"10387_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70447","volume":"132","author":"E Nicol\u00f2","year":"2026","unstructured":"Nicol\u00f2, E., Bertucci, F., Boussen, H., et al. (2026). Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025. Cancer, 132, Article e70447. https:\/\/doi.org\/10.1002\/cncr.70447","journal-title":"Cancer"},{"key":"10387_CR17","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.21037\/tcr-23-368","volume":"12","author":"L Xia","year":"2023","unstructured":"Xia, L., Lai, J., Liu, X., et al. (2023). Epidemiological and survival outcomes of neuroendocrine carcinoma of the breast: A SEER data analysis. Translational Cancer Research, 12, 1951\u20131962. https:\/\/doi.org\/10.21037\/tcr-23-368","journal-title":"Translational Cancer Research"},{"key":"10387_CR18","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/s41379-018-0081-z","volume":"31","author":"G Krings","year":"2018","unstructured":"Krings, G., & Chen, Y. Y. (2018). Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma. Modern Pathology, 31, 1661\u20131674. https:\/\/doi.org\/10.1038\/s41379-018-0081-z","journal-title":"Modern Pathology"},{"key":"10387_CR19","doi-asserted-by":"publisher","unstructured":"Perou, C.M., Sorlie, T., Eisen, M.B., et al. (2000). Molecular portraits of human breast tumours. Nature\u00a0, 406: 747\u2013752.\u00a0https:\/\/doi.org\/10.1038\/35021093.","DOI":"10.1038\/35021093"},{"key":"10387_CR20","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1158\/1538-7445.Am2026-1181","volume":"86","author":"ES Villodre","year":"2026","unstructured":"Villodre, E. S., Manyam, G., Hu, X., et al. (2026). Abstract 1181: Transcriptomic analysis of NDRG1 amplification in aggressive breast cancer. Cancer Research, 86, 1181\u20131181. https:\/\/doi.org\/10.1158\/1538-7445.Am2026-1181","journal-title":"Cancer Research"},{"key":"10387_CR21","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1158\/1538-7445.Am2026-3763","volume":"86","author":"S Shivhare","year":"2026","unstructured":"Shivhare, S., Sanchez, C., Larson, R., et al. (2026). Abstract 3763: CCR7 expression and spatial distribution in inflammatory breast cancer: A baseline characterization for therapeutic targeting. Cancer Research, 86, 3763\u20133763. https:\/\/doi.org\/10.1158\/1538-7445.Am2026-3763","journal-title":"Cancer Research"},{"key":"10387_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35238-w","volume":"14","author":"S Tietscher","year":"2023","unstructured":"Tietscher, S., Wagner, J., Anzeneder, T., et al. (2023). A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer. Nature Communications, 14, Article 98. https:\/\/doi.org\/10.1038\/s41467-022-35238-w","journal-title":"Nature Communications"},{"key":"10387_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13040604","author":"F Galati","year":"2023","unstructured":"Galati, F., Magri, V., Arias-Cadena, P. A., et al. (2023). Pregnancy-associated breast cancer: A diagnostic and therapeutic challenge. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics13040604","journal-title":"Diagnostics"},{"key":"10387_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204372","volume":"13","author":"T Fouad","year":"2018","unstructured":"Fouad, T., Ueno, N., Ensor, J., et al. (2018). Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. PLoS ONE, 13, Article e0204372. https:\/\/doi.org\/10.1371\/journal.pone.0204372","journal-title":"PLoS ONE"},{"key":"10387_CR25","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1016\/s1470-2045(17)30192-4","volume":"18","author":"TM Fouad","year":"2017","unstructured":"Fouad, T. M., Barrera, A. M., Reuben, J. M., et al. (2017). Inflammatory breast cancer: A proposed conceptual shift in the UICC-AJCC TNM staging system. Lancet Oncology, 18, e228\u2013e232. https:\/\/doi.org\/10.1016\/s1470-2045(17)30192-4","journal-title":"Lancet Oncology"},{"key":"10387_CR26","doi-asserted-by":"publisher","first-page":"e298","DOI":"10.1016\/j.ijrobp.2024.07.662","volume":"120","author":"EL Braschi","year":"2024","unstructured":"Braschi, E. L., Yang, Y., Stauder, M. C., et al. (2024). Rare but relevant: Exploring factors behind the exclusion of inflammatory breast cancer from breast cancer clinical trials. International Journal of Radiation Oncology*Biology*Physics, 120, e298\u2013e299. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.07.662","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"10387_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/annonc\/mdq345","volume":"22","author":"S Dawood","year":"2011","unstructured":"Dawood, S., Merajver, S. D., Viens, P., et al. (2011). International expert panel on inflammatory breast cancer: Consensus statement for standardized diagnosis and treatment. Annals of Oncology, 22, 515\u2013523. https:\/\/doi.org\/10.1093\/annonc\/mdq345","journal-title":"Annals of Oncology"},{"key":"10387_CR28","doi-asserted-by":"publisher","first-page":"25848","DOI":"10.18632\/oncotarget.15667","volume":"8","author":"J Arora","year":"2017","unstructured":"Arora, J., Sauer, S. J., Tarpley, M., et al. (2017). Inflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: Use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategies. Oncotarget, 8, 25848\u201325863. https:\/\/doi.org\/10.18632\/oncotarget.15667","journal-title":"Oncotarget"},{"key":"10387_CR29","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1200\/JCO.2026.44.16_suppl.1138","volume":"44","author":"ER Lopez","year":"2026","unstructured":"Lopez, E. R., Alexander, A., Marx, A., et al. (2026). Clinical and translational analysis of a phase Ib\/II combination of atezolizumab, cobimetinib, and eribulin (ACE) to demonstrate inflammatory and metabolic programs define divergent response states. Journal of Clinical Oncology, 44, 1138\u20131138. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.1138","journal-title":"Journal of Clinical Oncology"},{"key":"10387_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-02162-y","volume":"28","author":"A Nasrazadani","year":"2025","unstructured":"Nasrazadani, A., Tidwell, R. S., Kai, M., et al. (2025). Retrospective review of metastatic hormone receptor-positive inflammatory breast cancer patients reveals poor responses to cyclin dependent kinase 4\/6 inhibition. Breast Cancer Research, 28, Article 8. https:\/\/doi.org\/10.1186\/s13058-025-02162-y","journal-title":"Breast Cancer Research"},{"key":"10387_CR31","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon, D., Lipatov, O., Nowecki, Z., et al. (2024). Ribociclib plus endocrine therapy in early breast cancer. New England Journal of Medicine, 390, 1080\u20131091. https:\/\/doi.org\/10.1056\/NEJMoa2305488","journal-title":"New England Journal of Medicine"},{"key":"10387_CR32","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston, S. R. D., Harbeck, N., Hegg, R., et al. (2020). Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE). Journal of Clinical Oncology, 38, 3987\u20133998. https:\/\/doi.org\/10.1200\/JCO.20.02514","journal-title":"Journal of Clinical Oncology"},{"key":"10387_CR33","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/jco.22.00338","volume":"40","author":"F-C Bidard","year":"2022","unstructured":"Bidard, F.-C., Kaklamani, V. G., Neven, P., et al. (2022). Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: Results from the randomized phase III EMERALD trial. Journal of Clinical Oncology, 40, 3246\u20133256. https:\/\/doi.org\/10.1200\/jco.22.00338","journal-title":"Journal of Clinical Oncology"},{"key":"10387_CR34","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.annonc.2025.11.018","volume":"37","author":"KL Jhaveri","year":"2026","unstructured":"Jhaveri, K. L., Neven, P., Casalnuovo, M. L., et al. (2026). Imlunestrant with or without abemaciclib in advanced breast cancer: Updated efficacy results from the phase III EMBER-3 trial. Annals of Oncology, 37, 532\u2013543. https:\/\/doi.org\/10.1016\/j.annonc.2025.11.018","journal-title":"Annals of Oncology"},{"key":"10387_CR35","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2505725","volume":"393","author":"M Campone","year":"2025","unstructured":"Campone, M., De Laurentiis, M., Jhaveri, K., et al. (2025). Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer. New England Journal of Medicine, 393, 556\u2013568. https:\/\/doi.org\/10.1056\/NEJMoa2505725","journal-title":"New England Journal of Medicine"},{"key":"10387_CR36","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","volume":"393","author":"FC Bidard","year":"2025","unstructured":"Bidard, F. C., Mayer, E. L., Park, Y. H., et al. (2025). First-line camizestrant for emerging ESR1-mutated advanced breast cancer. New England Journal of Medicine, 393, 569\u2013580. https:\/\/doi.org\/10.1056\/NEJMoa2502929","journal-title":"New England Journal of Medicine"},{"key":"10387_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2026.102610","volume":"7","author":"Y Dai","year":"2026","unstructured":"Dai, Y., Pan, X., Guo, S., et al. (2026). Tumor microenvironment transcriptional activity enables robust stratification of chemotherapy response in triple-negative breast cancer. Cell Reports Medicine, 7, Article 102610. https:\/\/doi.org\/10.1016\/j.xcrm.2026.102610","journal-title":"Cell Reports Medicine"},{"key":"10387_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10469-9","author":"Y Yan","year":"2026","unstructured":"Yan, Y., Lin, Y., Kumar, T., et al. (2026). Ecotypes of triple-negative breast cancer in response to chemotherapy. Nature. https:\/\/doi.org\/10.1038\/s41586-026-10469-9","journal-title":"Nature"},{"key":"10387_CR39","doi-asserted-by":"publisher","first-page":"e13080","DOI":"10.1200\/JCO.2026.44.16_suppl.e13080","volume":"44","author":"AS Raghavendra","year":"2026","unstructured":"Raghavendra, A. S., Tarasov, A., Mouabbi, J. A., et al. (2026). Real-world clinical utility of comprehensive genomic and transcriptomic profiling in metastatic breast cancer (mBC). Journal of Clinical Oncology, 44, e13080\u2013e13080. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.e13080","journal-title":"Journal of Clinical Oncology"},{"key":"10387_CR40","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2026.44.16_suppl.587","volume":"44","author":"JA Mouabbi","year":"2026","unstructured":"Mouabbi, J. A., Raghavendra, A. S., Adesoye, T., et al. (2026). Distant recurrence\u2013free survival in invasive lobular carcinoma (ILC) with isolated tumor cells: Does pN0(i+) behave like node-negative or node-positive disease? Journal of Clinical Oncology, 44, 587\u2013587. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.587","journal-title":"Journal of Clinical Oncology"},{"key":"10387_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-025-03750-w","volume":"25","author":"Y Yu","year":"2025","unstructured":"Yu, Y., Ruan, L., et al. (2025). Integrated single-cell and bulk transcriptomic analysis identifies a novel macrophage subtype associated with poor prognosis in breast cancer. Cancer Cell International, 25, 1\u201314. https:\/\/doi.org\/10.1186\/s12935-025-03750-w","journal-title":"Cancer Cell International"},{"key":"10387_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2025.100888","volume":"5","author":"F Liu","year":"2025","unstructured":"Liu, F., Ding, Y., Xu, Z., et al. (2025). Single-cell profiling of bone metastasis ecosystems from multiple cancer types reveals convergent and divergent mechanisms of bone colonization. Cell Genomics, 5, Article 100888. https:\/\/doi.org\/10.1016\/j.xgen.2025.100888","journal-title":"Cell Genomics"},{"key":"10387_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101511","volume":"5","author":"L Xu","year":"2024","unstructured":"Xu, L., Saunders, K., Huang, S. P., et al. (2024). A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response. Cell Reports Medicine, 5, Article 101511. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101511","journal-title":"Cell Reports Medicine"},{"key":"10387_CR44","doi-asserted-by":"publisher","first-page":"e12594","DOI":"10.1200\/JCO.2026.44.16_suppl.e12594","volume":"44","author":"A Nasrazadani","year":"2026","unstructured":"Nasrazadani, A., Lim, B., Alexander, A., et al. (2026). Examining the tumor microbiology and microenvironment of patients with triple-negative inflammatory breast cancer receiving KEYNOTE-522. Journal of Clinical Oncology, 44, e12594\u2013e12594. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.e12594","journal-title":"Journal of Clinical Oncology"},{"key":"10387_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08593-4","volume":"10","author":"JL Caswell-Jin","year":"2019","unstructured":"Caswell-Jin, J. L., McNamara, K., Reiter, J. G., et al. (2019). Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy. Nature Communications, 10, Article 657. https:\/\/doi.org\/10.1038\/s41467-019-08593-4","journal-title":"Nature Communications"},{"key":"10387_CR46","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.90733","volume":"1","author":"J Kim","year":"2016","unstructured":"Kim, J., de Sampaio, P. C., Lundy, D. M., et al. (2016). Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy. JCI Insight, 1, Article e90733. https:\/\/doi.org\/10.1172\/jci.insight.90733","journal-title":"JCI Insight"},{"key":"10387_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002136","volume":"13","author":"G Goh","year":"2016","unstructured":"Goh, G., Schmid, R., Guiver, K., et al. (2016). Clonal evolutionary analysis during HER2 blockade in HER2-positive inflammatory breast cancer: A phase II open-label clinical trial of afatinib +\/- vinorelbine. PLoS Medicine, 13, Article e1002136. https:\/\/doi.org\/10.1371\/journal.pmed.1002136","journal-title":"PLoS Medicine"},{"key":"10387_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00876-y","author":"A Bartolomucci","year":"2025","unstructured":"Bartolomucci, A., Nobrega, M., Ferrier, T., et al. (2025). Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. npj Precision Oncology. https:\/\/doi.org\/10.1038\/s41698-025-00876-y","journal-title":"npj Precision Oncology"},{"key":"10387_CR49","doi-asserted-by":"publisher","first-page":"P1-01-28","DOI":"10.1158\/1557-3265.Sabcs24-p1-01-28","volume":"31","author":"J Chen","year":"2025","unstructured":"Chen, J., Meas, S., Bassett, R. L., et al. (2025). Abstract P1-01-28: Molecular residual disease precedes radiographic confirmation of recurrence in patients with stage III inflammatory breast cancer. Clinical Cancer Research, 31, P1-01\u201328. https:\/\/doi.org\/10.1158\/1557-3265.Sabcs24-p1-01-28","journal-title":"Clinical Cancer Research"},{"key":"10387_CR50","doi-asserted-by":"publisher","first-page":"GS3-01","DOI":"10.1158\/1557-3265.Sabcs24-gs3-01","volume":"31","author":"N Turner","year":"2025","unstructured":"Turner, N., Pimentel, I., Cescon, D., et al. (2025). Abstract GS3-01: Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w\/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy. Clinical Cancer Research, 31, GS3-01. https:\/\/doi.org\/10.1158\/1557-3265.Sabcs24-gs3-01","journal-title":"Clinical Cancer Research"},{"key":"10387_CR51","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1078-0432.Ccr-24-3472","volume":"31","author":"MJ Elliott","year":"2025","unstructured":"Elliott, M. J., Howarth, K., Main, S., et al. (2025). Ultrasensitive detection and monitoring of circulating tumor DNA using structural variants in early-stage breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 31, 1520\u20131532. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-3472","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10387_CR52","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.annonc.2025.01.021","volume":"36","author":"I Garcia-Murillas","year":"2025","unstructured":"Garcia-Murillas, I., Abbott, C. W., Cutts, R. J., et al. (2025). Whole genome sequencing-powered ctDNA sequencing for breast cancer detection. Annals of Oncology, 36, 673\u2013681. https:\/\/doi.org\/10.1016\/j.annonc.2025.01.021","journal-title":"Annals of Oncology"},{"key":"10387_CR53","doi-asserted-by":"publisher","first-page":"CT172","DOI":"10.1158\/1538-7445.AM2026-CT172","volume":"86","author":"R Upadhyay","year":"2026","unstructured":"Upadhyay, R., Alexander, A., Ye, Q., et al. (2026). Abstract CT172: A phase II trial of adjuvant PD-1 blockade with endocrine therapy in hormone receptor positive inflammatory breast cancer: Circulating biomarkers and molecular correlates of clinical outcomes. Cancer Research, 86, CT172.","journal-title":"Cancer Research"},{"key":"10387_CR54","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jamaoncol.2019.1838","volume":"5","author":"I Garcia-Murillas","year":"2019","unstructured":"Garcia-Murillas, I., Chopra, N., Comino-M\u00e9ndez, I., et al. (2019). Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncology, 5, 1473\u20131478. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1838","journal-title":"JAMA Oncology"},{"key":"10387_CR55","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/annonc\/mdz085","volume":"30","author":"S Hrebien","year":"2019","unstructured":"Hrebien, S., Citi, V., Garcia-Murillas, I., et al. (2019). Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Annals of Oncology, 30, 945\u2013952. https:\/\/doi.org\/10.1093\/annonc\/mdz085","journal-title":"Annals of Oncology"},{"key":"10387_CR56","doi-asserted-by":"publisher","unstructured":"O'Leary, B., Hrebien, S., Morden, J.P., et al.\u00a0(2018). Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun,\u00a0 9, Article 896.\u00a0\u00a0https:\/\/doi.org\/10.1038\/s41467-018-03215-x.","DOI":"10.1038\/s41467-018-03215-x"},{"key":"10387_CR57","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","volume":"25","author":"RC Coombes","year":"2019","unstructured":"Coombes, R. C., Page, K., Salari, R., et al. (2019). Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clinical Cancer Research, 25, 4255\u20134263. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3663","journal-title":"Clinical Cancer Research"},{"key":"10387_CR58","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","volume":"6","author":"M Radovich","year":"2024","unstructured":"Radovich, M., Jiang, G., et al. (2024). Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: Preplanned secondary analysis of the BRE12-158 randomized clinical trial. JAMA Oncology, 6, 1410\u20131415. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2295","journal-title":"JAMA Oncology"},{"key":"10387_CR59","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","volume":"41","author":"MJM Magbanua","year":"2023","unstructured":"Magbanua, M. J. M., Brown Swigart, L., Ahmed, Z., et al. (2023). Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell, 41, 1091-1102.e1094. https:\/\/doi.org\/10.1016\/j.ccell.2023.04.008","journal-title":"Cancer Cell"},{"key":"10387_CR60","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41586-023-06252-9","volume":"620","author":"T Kumar","year":"2023","unstructured":"Kumar, T., Nee, K., Wei, R., et al. (2023). A spatially resolved single-cell genomic atlas of the adult human breast. Nature, 620, 181\u2013191. https:\/\/doi.org\/10.1038\/s41586-023-06252-9","journal-title":"Nature"},{"key":"10387_CR61","doi-asserted-by":"publisher","unstructured":"Minussi, D. C., Sei, E., Wang, J., et al. Resolving clonal substructure from single cell genomic data using CopyKit. bioRxiv 2022: 2022.2003.2009.483497. https:\/\/doi.org\/10.1101\/2022.03.09.483497.","DOI":"10.1101\/2022.03.09.483497"},{"key":"10387_CR62","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/s41587-022-01233-1","volume":"40","author":"R Wei","year":"2022","unstructured":"Wei, R., He, S., Bai, S., et al. (2022). Spatial charting of single-cell transcriptomes in tissues. Nature Biotechnology, 40, 1190\u20131199. https:\/\/doi.org\/10.1038\/s41587-022-01233-1","journal-title":"Nature Biotechnology"},{"key":"10387_CR63","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41587-020-00795-2","volume":"39","author":"R Gao","year":"2021","unstructured":"Gao, R., Bai, S., Henderson, Y. C., et al. (2021). Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nature Biotechnology, 39, 599\u2013608. https:\/\/doi.org\/10.1038\/s41587-020-00795-2","journal-title":"Nature Biotechnology"},{"key":"10387_CR64","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2017.12.007","volume":"172","author":"AK Casasent","year":"2018","unstructured":"Casasent, A. K., Schalck, A., Gao, R., et al. (2018). Multiclonal invasion in breast tumors identified by topographic single cell sequencing. Cell, 172, 205-217.e212. https:\/\/doi.org\/10.1016\/j.cell.2017.12.007","journal-title":"Cell"},{"key":"10387_CR65","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.cell.2018.03.041","volume":"173","author":"C Kim","year":"2018","unstructured":"Kim, C., Gao, R., Sei, E., et al. (2018). Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell, 173, 879-893.e813. https:\/\/doi.org\/10.1016\/j.cell.2018.03.041","journal-title":"Cell"},{"key":"10387_CR66","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cell.2020.03.034","volume":"181","author":"M Monje","year":"2020","unstructured":"Monje, M., Borniger, J. C., D\u2019Silva, N. J., et al. (2020). Roadmap for the emerging field of cancer neuroscience. Cell, 181, 219\u2013222. https:\/\/doi.org\/10.1016\/j.cell.2020.03.034","journal-title":"Cell"},{"key":"10387_CR67","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","volume":"27","author":"A Bassez","year":"2021","unstructured":"Bassez, A., Vos, H., Van Dyck, L., et al. (2021). A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nature Medicine, 27, 820\u2013832. https:\/\/doi.org\/10.1038\/s41591-021-01323-8","journal-title":"Nature Medicine"},{"key":"10387_CR68","doi-asserted-by":"publisher","first-page":"7440","DOI":"10.1158\/1538-7445.Am2026-7440","volume":"86","author":"DA Pedroza","year":"2026","unstructured":"Pedroza, D. A., Kang, S. W., Zhang, X.-F., et al. (2026). Abstract 7440: Characterization of the metastatic TIME via spatial transcriptomics reveals unique cellular phenotypes post anti-CSF-1R and immuno-chemotherapy. Cancer Research, 86, 7440\u20137440. https:\/\/doi.org\/10.1158\/1538-7445.Am2026-7440","journal-title":"Cancer Research"},{"key":"10387_CR69","doi-asserted-by":"publisher","unstructured":"Voissi\u00e8re, A., Gomez-Roca, C., Chabaud, S., et al. (2023). The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.\u00a0Science Translational Medicine, 16, eadd1834. https:\/\/doi.org\/10.1126\/scitranslmed.add1834","DOI":"10.1126\/scitranslmed.add1834"},{"key":"10387_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17414-y","volume":"11","author":"M Terranova-Barberio","year":"2020","unstructured":"Terranova-Barberio, M., Pawlowska, N., Dhawan, M., et al. (2020). Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nature Communications, 11, Article 3584. https:\/\/doi.org\/10.1038\/s41467-020-17414-y","journal-title":"Nature Communications"},{"key":"10387_CR71","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41556-019-0373-7","volume":"21","author":"IS Kim","year":"2019","unstructured":"Kim, I. S., Gao, Y., Welte, T., et al. (2019). Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms. Nature Cell Biology, 21, 1113\u20131126. https:\/\/doi.org\/10.1038\/s41556-019-0373-7","journal-title":"Nature Cell Biology"},{"key":"10387_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2024.110892","volume":"116","author":"L Shi","year":"2024","unstructured":"Shi, L., Zhang, Z., Huang, Y., et al. (2024). FOXCUT regulates the malignant phenotype of triple-negative breast cancer via the miR-337-3p\/ANP32E axis. Genomics, 116, Article 110892. https:\/\/doi.org\/10.1016\/j.ygeno.2024.110892","journal-title":"Genomics"},{"key":"10387_CR73","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/cm9.0000000000002700","volume":"137","author":"X Yu","year":"2024","unstructured":"Yu, X., Qian, F., Zhang, X., et al. (2024). Promotion effect of FOXCUT as a microRNA sponge for miR-24-3p on progression in triple-negative breast cancer through the p38 MAPK signaling pathway. Chinese Medical Journal (English Edition), 137, 105\u2013114. https:\/\/doi.org\/10.1097\/cm9.0000000000002700","journal-title":"Chinese Medical Journal (English Edition)"},{"key":"10387_CR74","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-3714","author":"S Singh","year":"2022","unstructured":"Singh, S., Lee, N., Pedroza, D., et al. (2022). Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer. Cancer Research. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-3714","journal-title":"Cancer Research"},{"key":"10387_CR75","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41590-018-0207-y","volume":"19","author":"D Huang","year":"2018","unstructured":"Huang, D., Chen, J., Yang, L., et al. (2018). NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nature Immunology, 19, 1112\u20131125. https:\/\/doi.org\/10.1038\/s41590-018-0207-y","journal-title":"Nature Immunology"},{"key":"10387_CR76","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41590-019-0400-7","volume":"20","author":"Q Hu","year":"2019","unstructured":"Hu, Q., Ye, Y., Chan, L. C., et al. (2019). Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nature Immunology, 20, 835\u2013851. https:\/\/doi.org\/10.1038\/s41590-019-0400-7","journal-title":"Nature Immunology"},{"key":"10387_CR77","doi-asserted-by":"publisher","first-page":"LBA109","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","volume":"43","author":"SM Tolaney","year":"2025","unstructured":"Tolaney, S. M., de Azambuja, E., Kalinsky, K., et al. (2025). Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study. Journal of Clinical Oncology, 43, LBA109\u2013LBA109. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA109","journal-title":"Journal of Clinical Oncology"},{"key":"10387_CR78","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","volume":"393","author":"J Cort\u00e9s","year":"2025","unstructured":"Cort\u00e9s, J., Punie, K., Barrios, C., et al. (2025). Sacituzumab govitecan in untreated, advanced triple-negative breast cancer. New England Journal of Medicine, 393, 1912\u20131925. https:\/\/doi.org\/10.1056\/NEJMoa2511734","journal-title":"New England Journal of Medicine"},{"key":"10387_CR79","doi-asserted-by":"publisher","unstructured":"Cortes, J., Cescon, D., Rugo, H., et al.\u00a0(2020)\u00a0Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial - The Lancet. The Lancet 2020; 396: 1817\u20131828.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(20)32531-9.","DOI":"10.1016\/S0140-6736(20)32531-9"},{"key":"10387_CR80","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1158\/1538-7445.AM2026-3744","volume":"86","author":"H Gao","year":"2026","unstructured":"Gao, H., Upadhyay, R., Alexander, A., et al. (2026). Peripheral immune indices predict pathologic complete response and residual cancer burden in inflammatory breast cancers. Cancer Research, 86, 3744\u20133744.","journal-title":"Cancer Research"},{"key":"10387_CR81","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","volume":"579","author":"TD Wu","year":"2020","unstructured":"Wu, T. D., Madireddi, S., de Almeida, P. E., et al. (2020). Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature, 579, 274\u2013278. https:\/\/doi.org\/10.1038\/s41586-020-2056-8","journal-title":"Nature"},{"key":"10387_CR82","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41587-023-01697-9","volume":"41","author":"MR Vahid","year":"2023","unstructured":"Vahid, M. R., Brown, E. L., Steen, C. B., et al. (2023). High-resolution alignment of single-cell and spatial transcriptomes with CytoSPACE. Nature Biotechnology, 41, 1543\u20131548. https:\/\/doi.org\/10.1038\/s41587-023-01697-9","journal-title":"Nature Biotechnology"},{"key":"10387_CR83","doi-asserted-by":"publisher","unstructured":"Zheng, G.X., Terry, J.M., Belgrader, P., et al. (2017) Massively parallel digital transcriptional profiling of single cells. Nat Commun,\u00a0 8: 14049.\u00a0https:\/\/doi.org\/10.1038\/ncomms14049.","DOI":"10.1038\/ncomms14049"},{"key":"10387_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran, D., Hu, Z., & Butte, A. J. (2017). XCell: Digitally portraying the tissue cellular heterogeneity landscape. Genome Biology, 18, Article 220. https:\/\/doi.org\/10.1186\/s13059-017-1349-1","journal-title":"Genome Biology"},{"key":"10387_CR85","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1158\/1538-7445.AM2024-4852","volume":"84","author":"A Nasrazadani","year":"2024","unstructured":"Nasrazadani, A., Kai, M., Layman, R., et al. (2024). High brain relapse rates in stage III triple negative inflammatory breast cancer are independent of systemic therapy. Cancer Research, 84, 4852\u20134852.","journal-title":"Cancer Research"},{"key":"10387_CR86","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/jnci\/djy221","volume":"111","author":"JM Unger","year":"2019","unstructured":"Unger, J. M., Vaidya, R., Hershman, D. L., et al. (2019). Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. Journal of the National Cancer Institute, 111, 245\u2013255. https:\/\/doi.org\/10.1093\/jnci\/djy221","journal-title":"Journal of the National Cancer Institute"},{"issue":"pkz103","key":"10387_CR87","doi-asserted-by":"publisher","first-page":"20191216","DOI":"10.1093\/jncics\/pkz103","volume":"4","author":"OM Fayanju","year":"2020","unstructured":"Fayanju, O. M., Ren, Y., Thomas, S. M., et al. (2020). A case-control study examining disparities in clinical trial participation among breast surgical oncology patients. JNCI Cancer Spectr, 4(pkz103), 20191216. https:\/\/doi.org\/10.1093\/jncics\/pkz103","journal-title":"JNCI Cancer Spectr"},{"issue":"229\u2013238","key":"10387_CR88","doi-asserted-by":"publisher","first-page":"20201008","DOI":"10.1007\/s10549-020-05938-2","volume":"185","author":"HG Abraham","year":"2021","unstructured":"Abraham, H. G., Xia, Y., Mukherjee, B., et al. (2021). Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database. Breast Cancer Research and Treatment, 185(229\u2013238), 20201008. https:\/\/doi.org\/10.1007\/s10549-020-05938-2","journal-title":"Breast Cancer Research and Treatment"},{"key":"10387_CR89","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7574946","author":"RA Denu","year":"2017","unstructured":"Denu, R. A., Hampton, J. M., Currey, A., et al. (2017). Racial and socioeconomic disparities are more pronounced in inflammatory breast cancer than other breast cancers. Journal of Cancer Epidemiology. https:\/\/doi.org\/10.1155\/2017\/7574946","journal-title":"Journal of Cancer Epidemiology"},{"key":"10387_CR90","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6905","volume":"13","author":"MW Donzo","year":"2024","unstructured":"Donzo, M. W., Nguyen, G., Nemeth, J. K., et al. (2024). Effects of socioeconomic status on enrollment in clinical trials for cancer: A systematic review. Cancer Medicine, 13, Article e6905. https:\/\/doi.org\/10.1002\/cam4.6905","journal-title":"Cancer Medicine"},{"key":"10387_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2025.100114","volume":"7","author":"Y Uehara","year":"2025","unstructured":"Uehara, Y., Koyama, T., Katsuya, Y., et al. (2025). Impact of travel costs on disparities in precision oncology clinical trials. ESMO Real World Data and Digital Oncology, 7, Article 100114. https:\/\/doi.org\/10.1016\/j.esmorw.2025.100114","journal-title":"ESMO Real World Data and Digital Oncology"},{"issue":"945\u2013953","key":"10387_CR92","doi-asserted-by":"publisher","first-page":"20250723","DOI":"10.1016\/j.jmoldx.2025.06.006","volume":"27","author":"PS Henkel","year":"2025","unstructured":"Henkel, P. S., Aas, E., Russnes, H. G., et al. (2025). Microcosting study of genomic profiling for precision cancer medicine: Application from the National Infrastructure for Precision Diagnostics in Norway. The Journal of Molecular Diagnostics, 27(945\u2013953), 20250723. https:\/\/doi.org\/10.1016\/j.jmoldx.2025.06.006","journal-title":"The Journal of Molecular Diagnostics"},{"key":"10387_CR93","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","volume":"36","author":"JD Merker","year":"2018","unstructured":"Merker, J. D., Oxnard, G. R., Compton, C., et al. (2018). Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. Journal of Clinical Oncology, 36, 1631\u20131641. https:\/\/doi.org\/10.1200\/JCO.2017.76.8671","journal-title":"Journal of Clinical Oncology"},{"key":"10387_CR94","doi-asserted-by":"publisher","unstructured":"Bettegowda, C., Sausen, M., Leary R.J., et al. (2014). Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med,\u00a06(224), 224ra24. https:\/\/doi.org\/10.1126\/scitranslmed.3007094.","DOI":"10.1126\/scitranslmed.3007094"},{"key":"10387_CR95","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1200\/jco.23.02581","volume":"42","author":"B Freidlin","year":"2024","unstructured":"Freidlin, B., & Korn, E. L. (2024). Efficiency of biomarker-driven clinical trial designs. Journal of Clinical Oncology, 42, 1454\u20131455. https:\/\/doi.org\/10.1200\/jco.23.02581","journal-title":"Journal of Clinical Oncology"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10387-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10387-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10387-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:13:06Z","timestamp":1792663986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10387-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":95,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10387"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10387-2","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"18 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The views expressed in this Perspective belong to the authors and do not represent the official position of The University of Texas MD Anderson Cancer Center, Baylor College of Medicine, or any funding agency.","order":1,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"80"}}